James Crowe is the director of the Vanderbilt Vaccine Center, a professor of Pediatrics, Pathology, Microbiology, and Immunology, and the Ann Scott Carell Chair of the Vanderbilt University Medical Center. His laboratory group studies the human immune response to infection for a variety of major human pathogens, including emerging infections. He is the director of the Human Immunome Project, an ambitious effort to identify the sequence of all transcripts for human adaptive immune receptors. He is an elected member of the National Academy of Medicine and the National Academy of Inventors. His research group uses a broad array of techniques including molecular and cellular biology, state-of-the-art imaging and flow cytometry, bioinformatics, and bioengineering approaches to attack scientific problems at the forefront of immunity research. Crowe’s group has been widely recognized as a leader in antibody sciences, receiving awards such as the Best Academic Research Team as part of the 11th Annual Vaccine Industry Excellence Awards at the World Vaccine Congress, the 2019 Merck Future Insight Prize for Pandemic Preparedness, and large-scale research grants and contracts from the NIH and DoD, including the DARPA Pandemic Prevention Program (P3).